MERZ

31.1.2020 09:04:13 CET | Business Wire | Press release

Merz Aesthetics Presents Data at the IMCAS World Congress 2020

Merz, a global leader in medical aesthetics, announced today that data on the Merz Aesthetics product portfolio, including Belotero^® , Cellfina^® and Radiesse^® will be featured in oral and poster presentations at the 2020 International Master Course on Aging Science (IMCAS) World Congress, to be held from 30 January to 1 February 2020 in Paris, France.

“This meeting provides a platform for Merz Aesthetics to not only foster education and continuous training but also, to engage in thoughtful industry conversations while connecting with medical aesthetics physicians and fellow industry leaders from around the world,” said Bob Rhatigan, CEO of Merz Aesthetics. “We are grateful that our heritage and innovation in this space allows us to partner with world-renowned medical aesthetic experts, to share research on the diversified Merz Aesthetics product portfolio at the IMCAS World Congress.”

In addition to the poster presentations listed below, Merz Aesthetics is sponsoring the symposium event “Facial Rejuvenation: Interactive Sessions to Level-Up Your Injection Skills”, to be held on Saturday, 1 February at 10.30h – 12.30h, Room Amphi Bleu . The session will be opened by Bob Rhatigan, CEO of Merz Aesthetics and will include treatment insights from four international expert speakers:

Dr. Tatjana Pavicic – Dermatologist, Germany
Dr. Kate Goldie – Aesthetic Physician, United Kingdom
Prof. Yana Yutskovskaya – Dermatologist, Russia
Dr. Jani van Loghem – Aesthetic Physician, Netherlands

Oral Presentations

Independent presentations including data on the Merz Aesthetics portfolio:

What’s new in minimally invasive treatments

Update on dermal fillers (99921) – Kate Goldie, MBChB – UK. Thursday, 30 January, 17.54 – 18.06h, Amphi Bleu – Level 2

Body shaping and cellulite

Cellulite and skin laxity (93276). Doris Hexsel, Dermatologist – Brazil. Thursday, 30 January, 10.30 – 10.42h, Amphi Bleu – Level 2
Cellulite treatment update: how dimples, laxity and volume can be effectively treated (98147)¹ . Gabriela Casabona, MD– Spain. Thursday, 30 January, 11.18 – 11.30h, Amphi Bleu – Level 2

Biostimulatory fillers

Biostimulators: how dilution/diffusion interferes with outcome (93391). Gabriela Casabona, MD – Spain. Saturday, 1 February, 16.30 – 16.42, Room 143 - Level 1

E-Poster Presentations

E-Posters will be available for viewing at the Poster Zone on Level 2 , from Thursday, 30 January to Saturday, 1 February 2020 .

Distribution of cohesive polydensified matrix cross-linked hyaluronic acid volumizing gel in ex vivo human skin model. Christina Wollenburg, Jeanette Simon, Dr. Kay Marquardt, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.
Calcium hydroxylapatite microspheres provide organization into unorganized collagen networks leading to improvement of skin attractiveness. Gabriela Casabona, MD – Spain. Dr. Bartosch Nowag, Daniela Schäfer, Davide Greco, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.

BOCOUTURE^® Milestone

This year, Merz is also celebrating the ten-year anniversary of BOCOUTURE^® (incobotulinumtoxin A) in Europe. The botulinum toxin is part of the Merz Aesthetics portfolio and has received approval in 15 countries in Europe within the last ten years. A Booth Talk about “BOCOUTURE^® - 10 Years of a Unique Neurotoxin” with Dr. Thomas Rappl will take place Friday, 31 January, 16.00, Booth N° P251 .

About Merz

Merz is a global, diversified healthcare company based in Frankfurt, Germany. Privately-held for more than 111 years, the company operates in the areas of aesthetics, therapeutics and consumer care and is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In fiscal year 2018/19, Merz generated revenue of EUR 1,094 million; the company has a total workforce of 3,213 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com .

¹ Merz supported Investigator Initiated Trials

View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005133/en/

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom